Transplantation of embryonic dopamine neurons for severe Parkinson's disease.

By C. Olanow, T. Freeman, J. Kordower. New England Journal of Medicine, 2001

1,217 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/bda9245056cbac4f209c73f5b043927186bc240f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cognitive Neuroscience

1. Fred H. Gage
2. D. Abrous
3. M. Le Moal
4. Ted J. Kaptchuk
5. D. C. Lie
6. James Bradley Aimone
7. Wei Deng

In Molecular Biology

1. David Moher
2. Charles E. Murry
3. K. F. Schulz
4. D. Abrous
5. D. C. Lie
6. G. Keller
7. M. Le Moal
8. Douglas G. Altman

In Neurology

1. Fred H. Gage
2. D. Abrous
3. Z. Kokaia
4. D. C. Lie
5. M. Le Moal
6. O. Lindvall
7. M. Koehl
8. Douglas G. Altman

Citations in the corpus

• Functional anatomy of thalamus and basal ganglia (2002, neutral): “Transplantation of dopaminergic neurons [56] 3.”
• A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (2003, background): “Indeed, an earlier doubleblind, placebo-controlled trial failed to show significant clinical benefit after fetal nigral transplantation in a quality-of-life measure, the primary outcome variable.(22) In this study, transplantation was associated with modest improvement in more traditional motor outc”
• Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. (2008, result): “Early clinical trials with fetal tissue appeared promising (Lindvall and Hagell, 2001), but the results of randomized, controlled studies were less robust with modest improvements seen only in younger patients (Freed et al., 2001).”
• The Adult Substantia Nigra Contains Progenitor Cells with Neurogenic Potential (2002, background): “Based on previous animal studies, experimental therapies have sought to restore dopaminergic neurotransmission by exogenous cell replacement, which is achieved by transplanting fetal dopaminergic neurons into the striatum, the main target area of the SN (Olanow et al., 1996; Lindvall and Hagell, 200”
• Embryonic stem cells: prospects for developmental biology and cell therapy. (2005, result): “This issue has been highlighted by a clinical study, in which the transplantation of neural cells derived from fetal brain to Parkinson’s patients showed no significant benefit; moreover, 2 years after surgery, some treated patients developed persistent dyskinesia (128).”
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease (2003, result): “This result is in contrast to recent fetal transplant trials in which some patients experienced dyskinesias of unknown origin when off medicatio”
• Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. (2008, background): “Some placebos are also questionable from an ethical perspective, such as the use of simulated or sham surgery (27, 37, 107).”
• Adult neurogenesis: from precursors to network and physiology. (2005, background): “Although it generated a considerable amount of data, this approach has not proven very successful so far in living up to functional and therapeutic hopes (157, 217).”
• Stem cell therapy for human neurodegenerative disorders–how to make it work (2004, background): “Two recent sham surgery-controlled trials showed only modest improvemen”
• The Placebo Effect in Alternative Medicine: Can the Performance of a Healing Ritual Have Clinical Significance? (2002, background): “(The subsequent full report, which included long-term data, reported a less durable placebo effect [117].”